Various adipokines are reported to be associated with the development of heart failure (HF) through insulin resistance and chronic inflammation. Omentin-1 is a novel adipokine and is associated with incident coronary artery disease. However, it remains unclear whether serum omentin-1 levels are associated with cardiac prognosis in patients with HF.
Methods
We measured serum omentin-1 levels at admission in 136 consecutive patients with HF, and 20 control subjects without signs of significant heart disease. We prospectively followed patients with HF to endpoints of cardiac death or re-hospitalization for worsening HF.
Results
Serum omentin-1 levels were markedly lower in HF patients with cardiac events compared with to without. The patients who were in New York Heart Association (NYHA) functional class IV showed significantly lower serum omentin-1 levels compared to those in class II and III, whereas serum omentin-1 levels did not correlate with serum brain natriuretic peptide levels (r = 0.217, P = 0.011). We divided the HF patients into three groups based on the tertiles of serum omentin-1 level (low T1, middle T2, and high T3). Multivariate Cox hazard analysis showed that the lowest serum omentin-1 level (T1) was independently associated with cardiac events after adjustment for confounding factors (hazard ratio 5.78, 95% confidence interval 1.20-12.79). We divided the HF patients into two groups according to the median serum omentin-1 levels. Kaplan-Meier analysis revealed that the patients with low serum omentin-1 levels had a higher risk of cardiac events compared with those with high serum omentin-1 levels (log-rank test p < 0.001).
Conclusion
Decreased serum omentin-1 levels were associated with a poor cardiac outcome in patients with HF.
The online version of this article (doi:10.1186/1475-2840-13-84) contains supplementary material, which is available to authorized users.
Competing interests
The authors report that there is no duality of interest associated with this manuscript.
Authors’ contributions
TN, TW and IK contributed to discussions about study design and data analyses. SK, DK, MY, YO, and YH conceived and carried out experiments. TN and TW participated in the interpretation of the results and the writing of the manuscript. SN, HT, TA, TS, and TM helped with data collection. All authors have read and approved the final manuscript.
Abkürzungen
BMI
Body mass index
BNP
Brain natriuretic peptide
eGFR
Estimated glomerular filtration rate
ELISA
Sandwich enzyme-linked immunosorbent assay
HF
Heart failure
IDI
Integrated discrimination improvement
NRI
Net reclassification improvement
NYHA
New York heart association
SD
Standard deviation.
Background
Heart failure (HF) remain a major cause of death worldwide and has a poor prognosis despite advances in treatment [1]. Adipocytokines, such as tumor necrosis factor-alpha, interleukin-6, and plasminogen activator inhibitor-1, play a crucial role in the development of cardiovascular diseases through insulin resistance and chronic inflammation [2‐5]. Adipokines, such as adiponectin, are also reported to have anti-inflammatory, anti-oxidant, and anti-apoptotic properties, and are decreased in patients with cardiovascular disease [6‐9]. There has been a move to clarify the causal relationship between various adipokines and cardiovascular disease [10, 11].
Omentin-1 is a novel adipokine whose serum levels are decreased in obese individuals, and is associated with insulin resistance [12‐16]. Omentin-1 has been suggested to play a beneficial role in preventing atherosclerosis [17, 18], however, it remains unclear whether serum omentin-1 levels are associated with clinical outcome in patients with HF.
Anzeige
The purpose of this study was to clarify the impact of serum omentin-1 levels on cardiac prognosis in patients with HF.
Methods
Study population
We enrolled 136 consecutive patients who were admitted to the Yamagata University Hospital for treatment of worsening HF, diagnosis and pathophysiological investigations, or for therapeutic evaluation of HF. We also enrolled 20 control subjects without signs of significant heart disease.
A diagnosis of HF was based on a history of dyspnea and symptoms of exercise intolerance followed by pulmonary congestion, pleural effusion, or left ventricular enlargement by chest X-ray or echocardiography [19, 20]. Control subjects were excluded if they had significant coronary artery disease, systolic and diastolic dysfunction, valvular heart disease, or myocardial hypertrophy on echocardiography [21]. All patients gave written informed consent prior to their participation, and the protocol was approved by the institution’s Human Investigation Committee. The procedures were performed in accordance with the Helsinki Declaration.
Measurement of serum omentin-1 and brain natriuretic peptide levels
Blood samples were drawn at admission and centrifuged at 2,500 g for 15 minutes at 4°C within 30 minutes of collection. The serum was stored at -80°C until analysis. Serum omentin-1 concentrations were measured with a sandwich enzyme-linked immunosorbent assay (ELISA, Immuno-Biological Laboratories CO., Ltd., Gunma, Japan), according to the manufacturer’s instructions [22, 23]. The serum omentin-1 levels were measured in duplicate by an investigator unaware of the associated patients’ characteristics. Serum brain natriuretic peptide (BNP) concentrations were measured using a commercially available specific radio-immuno assay for human BNP (Shiono RIA BNP assay kit, Shionogi & Co., Ltd., Tokyo, Japan) [24].
Anzeige
Endpoints and follow-up
The patients were prospectively followed for a median duration of 399 ± 378 days. The end points were cardiac death, including death due to progressive HF, myocardial infarction, stroke and sudden cardiac death, and re-hospitalization for worsening HF. Sudden cardiac death was defined as death without definite premonitory symptoms or signs, and was confirmed by the attending physician. Two cardiologists who were blinded to the blood biomarker data reviewed the medical records and conducted telephone interviews to survey the incidence of cardiovascular events.
Statistical analysis
Data are presented as the mean ± standard deviation (SD). The Mann–Whitney U-test was used when the data were not distributed normally. If the data were not distributed normally, they were presented as medians with an interquartile range. The unpaired Student’s t-test and the chi-square test were used for comparisons of continuous and categorical variables, respectively. Comparison of data among three groups was performed by the Kruskal-Wallis test. Uni- and multivariate analyses with Cox proportional hazard regression were used to determine significant predictors of cardiovascular events. Cumulative overall and event-free survival rates were computed using the Kaplan-Meier method and were compared using the log-rank test. We calculated the net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) to measure the quantity of improvement for the correct reclassification and sensitivity according to the addition of serum omentin-1 levels to the prediction model [25]. NRI and IDI are new statistical measures to assess and quantify the improvement in risk prediction offered by a new marker. A P value < 0.05 was considered statistically significant. All statistical analyses were performed with a standard statistical program package (JMP version 10; SAS Institute, Cary, North Carolina, USA), and the R-3.0.2 with additional packages (Rcmdr, Epi, pROC, and PredictABEL).
Results
Comparison between patients with and without heart failure
The patients with HF had a lower BMI and left ventricular ejection fraction, and lower serum total cholesterol, triglyceride levels, and higher serum BNP levels compared with control subjects (Table 1).
Table 1
Baseline clinical characteristics
Control (n=20)
Heart failure (n=136)
P value
Age, years
65 ± 16
72 ± 12
0.034
Male, n (%)
11 (55)
76 (56)
0.941
NYHA functional class, II/III/IV
-
71/46/19
-
Etiology, n (%)
-
Dilated cardiomyopathy
-
29 (21)
Valvular heart disease
-
38 (28)
Ischemic heart disease
-
30 (22)
Hypertensive heart disease
-
14 (10)
Hypertrophic cardiomyopathy
-
9 (7)
Others
-
16 (12)
Presentation profile
Systolic pressure, mmHg
119 ± 22
117 ± 18
0.772
Diastolic pressure, mmHg
77 ± 10
74 ± 10
0.209
Body mass index, kg/m2
23.3 ± 3.4
21.7 ± 3.9
0.049
eGFR, ml/min/1.73m2
70 ± 24
62 ± 26
0.197
Blood biomarkers
Albumin, g/dl
3.8 ± 0.5
3.5 ± 0.6
0.091
Total cholesterol, mg/dl
185 ± 34
166 ± 39
0.042
Triglyceride, mg/dl
143 ± 96
91 ± 47
<0.001
LDLc, mg/dl
111 ± 28
100 ± 37
0.213
HDLc, mg/dl
52 ± 15
53 ± 23
0.831
hsCRP, mg/dl (IQR)
0.121 (0.040-0.551)
0.198 (0.064-0.606)
0.279
BNP, pg/ml (IQR)
82 (50–152)
484 (215–1251)
<0.001
Omentin-1, ng/ml (IQR)
494 (351–630)
305 (35–473)
0.035
Echocardiographic data
LV end-diastolic diameter, mm
53 ± 8
55 ± 11
0.438
LV ejection fraction, %
65 ± 9
50 ± 18
<0.001
Medications, n (%)
ACE inhibitors and/or ARBs
15 (75)
102 (75)
0.999
β blockers
15 (75)
103 (76)
0.943
Statins
10 (50)
51 (38)
0.321
Ca channel blockers
5 (25)
37 (27)
0.778
Data are presented as mean±SD or % unless otherwise indicated; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; BUN, Blood urea nitrogen; eGFR, estimated glomerular filtration rate; HDLc, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDLc, low density lipoprotein cholesterol; LV, left ventricular; NYHA, New York Heart Association.
Comparison between HF patients with and without cardiac events
There were 59 cardiac events including 17 deaths and 32 re-hospitalizations in patients with HF during the follow-up period (Table 2). The patients who experienced cardiac events were in a more severe New York Heart Association (NYHA) functional class, and had a lower estimated glomerular filtration rate, lower left ventricular ejection fraction, higher left ventricular end-diastolic diameter, and higher serum BNP levels compared with those who did not. Moreover, patients with cardiac events showed markedly lower serum omentin-1 levels compared with those without (Figure 1). There were no significant differences in etiologies of HF between patients with and without cardiac events (Table 2).
Table 2
Comparison of patients with or without cardiac event
Event (-) (n=77)
Event (+) (n=59)
P value
Age, years
71 ± 10
72 ± 14
0.687
Male, n (%)
40 (52)
36 (61)
0.480
NYHA functional class, II/III/IV
49/21/6
22/25/13
0.005
Etiology, n (%)
0.348
Dilated cardiomyopathy
12 (16)
17 (29)
-
Valvular heart disease
24 (31)
14 (24)
-
Ischemic heart disease
17 (22)
13 (22)
-
Hypertensive heart disease
8 (10)
6 (10)
-
Hypertrophic cardiomyopathy
6 (8)
3 (5)
-
Others
10 (13)
6 (10)
-
Presentation profile
Systolic pressure, mmHg
116 ± 18
118 ± 19
0.598
Diastolic pressure, mmHg
73 ± 9
74 ± 11
0.780
Body mass index, kg/m2
22.0 ± 4.4
21.4 ± 3.3
0.413
eGFR, ml/min/1.73m2
66 ± 27
57 ± 24
0.046
Blood biomarkers
Albumin, g/dl
3.5 ± 0.6
3.5 ± 0.6
0.539
Total cholesterol, mg/dl
169 ± 37
163 ± 42
0.398
Triglyceride, mg/dl
97 ± 48
84 ± 45
0.132
LDLc, mg/dl
101 ± 37
99 ± 37
0.731
HDLc, mg/dl
55 ± 29
52 ± 12
0.437
hsCRP, mg/dl (IQR)
0.174 (0.058-0.330)
0.267 (0.073-0.722)
0.308
BNP, pg/ml (IQR)
453 (248–1249)
512 (169–1255)
0.049
Omentin-1, ng/ml (IQR)
479 (323–661)
139 (57–402)
<0.001
Echocardiographic data
LV end-diastolic diameter, mm
53 ± 10
57 ± 10
0.011
LV ejection fraction, %
56 ± 17
45 ± 16
<0.001
Medications, n (%)
ACE inhibitors and/or ARBs
54 (70)
48 (81)
0.134
β blockers
52 (68)
51 (86)
0.029
Statins
23 (30)
28 (47)
0.460
Ca channel blockers
29 (3)
8 (14)
0.964
Data are presented as mean±SD or % unless otherwise indicated; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; BUN, Blood urea nitrogen; eGFR, estimated glomerular filtration rate; HDLc, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDLc, low density lipoprotein cholesterol; LV, left ventricular; NYHA, New York Heart Association.
×
Serum omentin-1 levels and HF severity
The patients who were in NYHA functional class IV showed significantly lower serum omentin-1 levels compared to those in class II and III (P = 0.029 vs. class II and P = 0.041 vs. class III, Figure 2A). On the other hand, serum omentin-1 levels were not significantly different between the patients who were in NYHA functional class II and III (P = 0.582). Furthermore, there was no relationship between the serum omentin-1 levels and the serum BNP levels (r = 0.217, Figure 2B).
×
Association between serum omentin-1 levels and cardiac events
We divided patients with HF into three groups according to the tertiles of serum omentin-1 levels. Multivariate Cox hazard analysis showed that the lowest serum omentin-1 levels (T1) were independently associated with cardiac events after adjustment for age, gender, NYHA functional class, left ventricular ejection fraction, and serum brain natriuretic peptide levels (hazard ratio 5.65, 95% confidence interval 2.61-12.20; Figure 3, Table 3). We divided the patients into two groups according to the median serum omentin-1 levels. Kaplan-Meier analysis revealed that the patients with low serum omentin-1 levels had a higher risk of cardiac events compared to those with high serum omentin-1 levels (log-rank test p < 0.001, Figure 4).
×
Table 3
Univariate and multivariate analyses for cardiac events
Univariate Analysis
Multivariate Analysis
HR
95% CI
P value
Adjusted HR*
95% CI
P value
Omentin-1
T3
1
Reference
Reference
1
Reference
Reference
T2
5.56
2.85-10.87
<0.001
4.15
2.03-8.47
<0.001
T1
6.29
1.30-13.06
<0.001
5.65
2.61-12.20
<0.001
*Adjusted HR after adjustment for age, gender, body mass index, NYHA functional class, left ventricular ejection fraction, serum triglycerides, serum HDLc levels, and serum BNP levels.
BNP, brain natriuretic peptide; CI, confidence interval; HDLc, high density lipoprotein cholesterol; HR, hazard ratio; NYHA, New York Heart Association; SD, standard deviation.
×
Net reclassification improvement and integrated discrimination improvement
To measure the quantity of improvement for the correct reclassification and sensitivity according to the addition of serum omentin-1 levels to the prediction model, we calculated the NRI and the IDI. The inclusion of serum omentin-1 levels in the prediction model (includes age, gender, NYHA functional class, left ventricular ejection fraction, and serum BNP levels) for the prediction of cardiac events, improved the NRI and IDI values, suggesting effective reclassification and discrimination (Table 4).
Table 4
Statistics for model fit and improvement with addition of serum omentin-1 level predicted on the prediction of cardiac events
Prediction model
Prediction model + omentin-1
P value
NRI (95% CI)
Reference
0.375 (0.129-0.620)
0.002
IDI (95% CI)
Reference
0.149 (0.087-0.211)
<0.001
Prediction model includes age, gender, NYHA functional class, left ventricular ejection fraction, and serum BNP levels.
BNP, brain natriuretic peptide; CI, confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification improvement; NYHA, New York Heart Association.
Discussion
The present study demonstrated that decreased serum omentin-1 levels predicted cardiac events in patients with HF. Serum omentin-1 level appears to be a novel prognostic marker for the risk stratification of patients with HF.
Anzeige
Various types of adipocytokines are reported to be a predictor of unfavorable cardiac outcomes in patients with HF [26]. In addition to their roles as predictors of cardiac outcome, a variety of adipocytokines have been associated with the development of HF through insulin resistance and chronic inflammation [14, 27‐29]. Serum adiponectin levels are reported to be correlated with BNP levels, and are associated with HF severity and unfavorable outcomes in patients with HF [30, 31]. Adiponectin has been suggested to play a role in the prevention of cardiovascular diseases via its anti-inflammatory, anti-oxidant, and anti-apoptotic properties [6‐9]. Recently, reports have shown several adipokines to have beneficial effects on cardiovascular diseases [32‐34]. However, the precise role of these adipokines remains unclear.
Omentin-1 is a 38 kDa novel adipokine identified in 2004 from visceral adipose tissue [12, 13]. Shibata et al. reported that decreased plasma omentin-1 levels predict the prevalence of coronary artery disease [18]. Yang et al. reported that omentin-1 enhances insulin-stimulated glucose uptake in human adipocytes and may regulate insulin sensitivity [13]. Yamawaki et al. reported that omentin-1 modulates vascular function and attenuates cyclooxygenase-2 expression and c-jun N-terminal kinase (JNK) activation in cytokine-stimulated endothelial cells [35, 36]. These studies all suggest that omentin-1 may improve insulin resistance and suppress vascular inflammation. Interestingly, Pan et al. suggested that omentin-1 expression and production are decreased with elevated inflammatory adipokines, such as tumor necrosis factor-alpha and interleukin-6, in patients with impaired glucose intolerance and newly diagnosed type 2 diabetes mellitus [37].
Unlike to adiponectin, serum omentin-1 was reported to decrease with chronic inflammation and oxidative stress in patients with HF. The bioactivity of omentin-1 appears multifaceted and remains to be fully defined. The present study showed no correlation between serum omentin-1 and BNP levels unlike adiponectin [30], suggesting that these markers indicate different features of the pathophysiological process of HF. Serum omentin-1 levels may represent a promising biomarker for cardiac prognosis, irrespective of serum BNP levels. The inclusion of serum omentin-1 levels in the prediction model (includes age, gender, NYHA functional class, left ventricular ejection fraction, and serum BNP levels) for the prediction of cardiac events, improved the NRI and IDI values, suggesting effective reclassification and discrimination.
The present study has certain limitations. Firstly, the sample size was relatively small and it was a single center study. Nonetheless, there was a significant relationship between serum omentin-1 levels and cardiac events. In addition, the inclusion of serum omentin-1 levels in the prediction model with conventional risk factors, including serum BNP levels, for the prediction of cardiac events, improved the NRI and IDI values. Secondly, there were no data for other adipocytokines. Further study is needed to clarify the association between serum omentin-1 and other adipocytokines in a large HF population.
Anzeige
In conclusion, decreased serum omentin-1 levels were associated with cardiac events in patients with HF, irrespective of serum BNP levels. Serum omentin-1 level appears to represent a novel prognostic marker for the risk stratification of patients with HF.
Acknowledgements
The authors would like to express their gratitude to the staff at the Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan for their kind cooperation while conducting this study. Research described in this manuscript was supported in part by a grant-in-aid for Scientific Research (No. 24591033) from the Ministry of Education Culture, Sport, Science, and Technology.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The authors report that there is no duality of interest associated with this manuscript.
Authors’ contributions
TN, TW and IK contributed to discussions about study design and data analyses. SK, DK, MY, YO, and YH conceived and carried out experiments. TN and TW participated in the interpretation of the results and the writing of the manuscript. SN, HT, TA, TS, and TM helped with data collection. All authors have read and approved the final manuscript.
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.
Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.